Reuters logo
10 months ago
BRIEF-China Biologic receives CFDA clinical trial approval for Human Antithrombin III
October 11, 2016 / 12:47 PM / 10 months ago

BRIEF-China Biologic receives CFDA clinical trial approval for Human Antithrombin III

Oct 11 (Reuters) - China Biologic Products Inc

* China Biologic receives CFDA clinical trial approval for Human Antithrombin III

* China Biologic Products Inc - China Biologic expects to commence clinical trials for ATIII product in 2017 and complete trials in two years or longer

* China Biologic Products-unit Shandong Taibang Biological Products obtained approval from CFDA to begin human clinical trials on Human Antithrombin III Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below